Zhen Su, Chief Executive Officer and Member Board of Directors at Marengo Therapeutics, shared on LinkedIn:
“Proud to be at SITC26 with this team, advancing a shared ambition: bringing the promise of next generation precision cancer immunotherapy to more patients beyond ICI.
Our STARt-002 oral presentation shared encouraging results for invikafusp alfa plus TRODELVY in metastatic triple-negative and HR-positive/HER2-negative breast cancer – including confirmed complete responses in both cohorts.
For patients in settings where checkpoint inhibition has offered limited benefit, these early findings give us motivation to keep pushing forward. We are exploring how selective T-cell activation could serve as a precision immune amplifier alongside ADCs.
Behind every scientific milestone are people who believe in the biology and do the hard work to translate it into potential medicines.
Grateful to our Marengo team, our investigators and collaborators at Gilead Sciences – and especially the patients and families making this research possible.
Much more work ahead, with patients at the center.”
You may also be interested in: Lisa Ebert: Presenting New Biomarker Findings in Melanoma Immunotherapy at SITC
